undamentalytics Newsletter
Sign in

Atara Biotherapeutics, Inc. revenue

Atara Biotherapeutics, Inc.'s revenue was $121m in fiscal 2025, down 6.3% on the year before. Since fiscal 2022 ($63.6m) it has grown at a compound 23.9% a year. Over the last twelve months it was $6.2m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue6491291216
Growth on the year before—−86.5%+>999%−6.3%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Atara Biotherapeutics, Inc. $6.2m -96.7% -3.4%
CG Oncology, Inc. $6.2m 1030.3% —
Fate Therapeutics Inc $6.5m -23.4% -62.1%
HCW Biologics Inc. $6.7m 700.2% 20.4%
Taysha Gene Therapies, Inc. $5.5m -32.3% —
Tscan Therapeutics, Inc. $7.1m 2.2% -24.3%

Compare with peers

Head to head: ATRA vs CGONATRA vs FATEATRA vs HCWB

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Atara Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Atara Biotherapeutics, Inc.